ASCO 2019 Lung Cancer: 36 Oral Presentations of the ASCO19 lung cancer track summarised – Medical Writer Agency | �ュ�鵝쒎�腰숁릭 | �ュ�野ヤ퐳 | MediPR

Non-Sponsored Content

ASCO 2019 LUNG CANCER TRACK

SPOTLIGHT ON LUNG CANCER

By: Stijn van den Borne, MSc | Last updated: 12th June 2019 | In: ASCO 2019 Annual Meeting, Chemotherapy, Conferences, Immunotherapy, Lung Cancer, Oncology, Radiology, Surgery, Targeted Therapies, Translational Research

Non-small cell lung cancer (NSCLC) was a key feature of the American Society of Clinical Oncology (ASCO) 2019 annual meeting. This year, exciting results with neoadjuvant immunotherapy (I-O) from the LCMC3, NEOSTAR, and GECP16/03_NADIM studies as well as combinations of I-O 혻and PARP-inhibitors with chemoradiation therapy (CRT) in the NCI-2015-01810, DETERRED, and M14-360/AFT-07 trials.혻Another highlight was the long-term data and sub-analysis of several pivotal studies with immune-checkpoint inhibitors in NSCLC, such as the KEYNOTE-101, KEYNOTE-189, IMpower150, and MYSTIC.

Furthermore, several studies presented data of novel and existing data of small molecule tyrosine kinase inhibitors for genetic rearrangements, including EGFR, cMET, ROS1, ALK, RET, NTRK, KRAS.혻Welcome to the summary of the ASCO 2019 lung cancer track.

Download the PPT

ASCO 2019 Lung Cancer Keywords

3GTKI, ABBV-399, afatinib, Alimta, ALK, Amgen, AP32788, Ariad Pharmaceuticals, AstraZeneca, atezolizumab, Avastin, bevacizumab, BioMarin, BLU-667, BMN-673, BMS, Boehringer Ingelheim, Bristol-Myers Squibb, c-ROS, capmatinib, carboplatin, carfilzomib, CEP7, cisplatin, cMET, CNS, CRT, Cyramza, Daiichi Sankyo, DLL3, docetaxel, durvalumab, EGFR, EGFR Ex19del, EGFR Ex20ins, EGFRwt, Eli Lilly, erlotinib, G12C, gefitinib, Genentech, Gilotrif, HGFR, HRRD, Imfinzi, INC280, Incyte, ipilimumab, Iressa, irinotecan, Janssen, JNJ-372, JNJ-61186372, Keytruda, KRAS, Kyprolis, Lorbrena, lorlatinib, lurbinectedin, Medivation, Mekinist, Merck, Merck KGaA, Merck Serono, Merckgroup, MET, metformin, MET�ex14, MSD, nivolumab, non-squamous cell lung cancer, Novartis, NSCLC, NTRK, NTRK1, NTRK2, NTRK3, Opdiva, osimertinib, paclitaxel, PD-1, PD-L1, pembrolizumab, pemetrexed, Pfizer, PharmaMar, PM01183, ramucirumab, repotrectinib, Roche, ROS1, rova-t, rovalpituzumab tesirine, SCLC, SMRP, squamous cell lung cancer, Stemcentrx, Tagrisso, TAK-788, Takeda, talazoparib, Talzenna, Tarceva, Tecentriq, teliso-V, telisotuzumab vedotin, tepotinib, TPS, TPX-0005, trametinib, tremelimumab, Turning Point Therapeutics, U3-1402, VAF, veliparib, vinolrebin, Yervoy

[pdf-embedder url="https://cdn.medi-paper.com/wp-content/uploads/2019/06/ASCO-2019-lung-cancer-NSCLC-ASCO19-SCLC-mesothelioma-KEYNOTE-189-KEYNOTE-001-IMpower150-MYSTIC-LCMC3-Lung-MAP-S1400G-S1400I-Flaura-CALGB-30901-DETERRED-COMPASS.pdf"]

Disclaimer

This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).